New Live Sound Clear, Korea University's medical technology holding subsidiary, obtains product approval from the Ministry of Food and Drug Safety
Feb 16, 2025
Digital therapy developed by New Live Co., Ltd. (CEO Song Jae-joon, professor of otolaryngology and head and neck surgery at Korea University Guro Hospital) has obtained product approval from the Ministry of Food and Drug Safety as the fifth digital treatment in Korea. It is the first digital treatment for tinnitus treatment in Korea.
Sound Clear predicts the patient's obstacles and treatment targets with AI by quantifying the patient's age, gender, frequency, and size of tinnitus, and then provides the most appropriate tinnitus treatment program for patients. It is a digital treatment for hospitals, and medical staff can download an app and use it for patients.
CEO Song Jae-joon said "The mental and physical dysfunction caused by the name is a disease that causes a lot of pain to patients, but the reality is that there is no clear treatment method. "This product approval allows us to provide more sophisticated and personalized treatment solutions for tinnitus, which provides new treatment options for patients suffering from tinnitus."
In addition, the electronic drug 'Solicle' developed by New Live has recently received product approval in Brazil, allowing it to target the South American market, mainly in Brazil. Electronic drugs are devices that treat diseases by stimulating the brain, and Soricle uses headphone equipment for both ears to electrically stimulate the ear area (outer branch) connected to the vagus nerve that controls the autonomic nerves. AI-controlled electrical stimulation increases brain blood flow and neurotransmitters, calming the auditory cortical excitation that causes tinnitus.
Meanwhile, NEURIVE, founded in 2018 by Song Jae-joon, a professor of otolaryngology and head and neck surgery at Korea University Hospital, is a medical technology holding subsidiary of Korea University and has been developing a 'electronic medical device' based on software and non-invasive VNS technology, which has drawn global attention in relation to degenerative brain diseases since its establishment in August 2018.
Sound Clear predicts the patient's obstacles and treatment targets with AI by quantifying the patient's age, gender, frequency, and size of tinnitus, and then provides the most appropriate tinnitus treatment program for patients. It is a digital treatment for hospitals, and medical staff can download an app and use it for patients.
CEO Song Jae-joon said "The mental and physical dysfunction caused by the name is a disease that causes a lot of pain to patients, but the reality is that there is no clear treatment method. "This product approval allows us to provide more sophisticated and personalized treatment solutions for tinnitus, which provides new treatment options for patients suffering from tinnitus."
In addition, the electronic drug 'Solicle' developed by New Live has recently received product approval in Brazil, allowing it to target the South American market, mainly in Brazil. Electronic drugs are devices that treat diseases by stimulating the brain, and Soricle uses headphone equipment for both ears to electrically stimulate the ear area (outer branch) connected to the vagus nerve that controls the autonomic nerves. AI-controlled electrical stimulation increases brain blood flow and neurotransmitters, calming the auditory cortical excitation that causes tinnitus.
Meanwhile, NEURIVE, founded in 2018 by Song Jae-joon, a professor of otolaryngology and head and neck surgery at Korea University Hospital, is a medical technology holding subsidiary of Korea University and has been developing a 'electronic medical device' based on software and non-invasive VNS technology, which has drawn global attention in relation to degenerative brain diseases since its establishment in August 2018.
|
This article was translated by Naver AI translator.
